Position in PTGX
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$1,124,181
+$171,365 QoQ
Shares Held
9,171
+1.4% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
1.13%
of 13F equity value
Holder Rank
#174
of 341 holders
Holding Since
Sep 2023
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026AlphaCentric Advisors LLC holds $32,614,824 across 48 Biotechnology names. PTGX ranks #10 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,002 | $2,484,643 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
48,355 | $1,711,283 | |
| 3 | ARGX |
Argenx SE
|
1,806 | $1,675,552 | |
| 4 | INCY |
Incyte Corp
|
14,451 | $1,638,165 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
6,531 | $1,598,592 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
11,533 | $1,530,775 | |
| 7 | INSM |
INSMED Inc
|
11,699 | $1,247,347 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
15,430 | $1,223,444 |
All Filings in PTGX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,124,181 | 9,171 | Shares | Other | 2026-07-24 | |
| 2026-03-31 | $952,816 | 9,040 | Shares | Other | 2026-05-07 | |
| 2025-12-31 | $746,669 | 8,549 | Shares | Other | 2026-02-12 | |
| 2024-12-31 | $274,947 | 7,123 | Shares | Other | 2025-01-31 | |
| 2024-09-30 | $1,125,000 | 25,000 | Shares | Other | 2024-10-30 | |
| 2024-06-30 | $866,250 | 25,000 | Shares | Other | 2024-07-25 | |
| 2024-03-31 | $723,250 | 25,000 | Shares | Other | 2024-04-24 | |
| 2023-12-31 | $687,900 | 30,000 | Shares | Other | 2024-02-14 | |
| 2023-09-30 | $725,580 | 43,500 | Shares | Other | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||